Peter Boström - UTU Research Portal

Peter Boström

- Associate Professor,
Surgery (Department of Clinical Medicine)

peter.bostrom@utu.fi

: https://orcid.org/0000-0003-3647-0015

10 of 12

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy (2016)
- Bladder Cancer
Boström PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BW, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy (2016)
- Journal of Urology
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy (2016)
- International Journal of Cancer
Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Bostrom PJ, Alanen K, Nurmi M, Nees M, Harkonen P
Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care (2016)
- Scandinavian Journal of Urology
Riikonen J, Kaipia A, Petas A, Horte A, Koskimaki J, Kahkonen E, Bostrom PJ, Paananen I, Kuisma J, Santti H, Matikainen M, Rannikko A
Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-alpha 2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study (2016)
- European Urology
Timo Marttila, Riikka Järvinen, Tapani Liukkonen, Erkki Rintala, Peter Boström, Marjo Seppänen, Teuvo Tammela, Pekka Hellström, Sirpa Aaltomaa, Markku Leskinen, Mika Raitanen, Eero Kaasinen
Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy (2016)
- Scientific Reports
Laajala TD, Seikkula H, Sadat FS, Mirtti T, Boström PJ, Elo LL.
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. (2016)
- Modern Pathology
Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.
Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method (2016)
- Journal of Magnetic Resonance Imaging
Ginsburg SB, Taimen P, Merisaari H, Vainio P, Boström PJ, Aronen HJ, Jambor I, Madabhushi A
Relaxation along fictitious field, diffusion-weighted imaging, and T2 mapping of prostate cancer: Prediction of cancer aggressiveness (2016)
- Magnetic Resonance in Medicine
Jambor I, Pesola M, Merisaari H, Taimen P, Boström PJ, Liimatainen T, Aronen HJ
Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction (2016)
- Magnetic Resonance in Medicine
Jambor I, Pesola M, Taimen P, Merisaari H, Boström PJ, Minn H, Liimatainen T, Aronen HJ
Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue (2016)
- Urologic Oncology: Seminars and Original Investigations
Alinezhad S, Vaananen RM, Tallgren T, Perez IM, Jambor I, Aronen H, Kahkonen E, Ettala O, Syvanen K, Nees M, Kallajoki M, Taimen P, Bostrom PJ, Pettersson K
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment (2016)
- Annals of Oncology
Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houede N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MAS, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BWG
Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer (2016)
- Minerva Urologica e Nefrologica
Antti P. Salminen, Ivan Jambor, Kari T. Syvänen, Peter J. Boström
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies (2016)
- PLoS ONE
Alinezhad S, Väänänen RM, Mattsson J, Li YF, Tallgren T, Ochoa NT, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M
Virtsarakkosyövän hoidossa valoa tunnelin päässä (2016)
- Lääkärilehti
Boström PJ
Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates (2015)
- BMC Urology
Vaananen RM, Ochoa NT, Bostrom PJ, Taimen P, Pettersson K
Differential predictive roles of A- and B-type nuclear lamins in prostate cancer progression (2015)
- PLoS ONE
Saarinen I, Mirtti T, Seikkula H, Boström PJ, Taimen P
Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization (2015)
- Magnetic Resonance Imaging
Merisaari H, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I
Erectile dysfunction cannot be used in primary screening of pre-diabetes (2015)
- Diabetes Research and Clinical Practice
Ettala OO, Korhonen PE, Syvanen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, Bostrom PJ
Eturauhasen sairaudet – Ennaltaehkäisy, tutkimukset ja hoito (2015) Boström Peter